Truth Seeker
New Member
Abstract
Prevalence of non-alcoholic steatohepatitis (NASH) Rises steadily in Western Countries with the obesity epidemic. NASH is associated with activation of liver fibrogenesis and predisposed to cirrhosis and associated morbidity mortalité. The cannabinoid system is increasingly have a crucial mediator emery of acute and chronic liver injury. Recent experimental and clinical data Indicate That activation of peripheral cannabinoid CB1 receptors Promotes insulin resistance and liver steatogenesis, Two key steps in the pathogenesis of non-alcoholic fatty liver disease. Moreover, CB1 receptors Enhance progression of liver fibrogenesis. These Findings provide statement a strong rationale for the use of CB1 antagonists in the management of NASH.
Summary
The prevalence of NASH is increasing in Western countries, along with that of obesity. NASH is associated with activation mechanisms of fibrogenesis with a risk of progression to cirrhosis and significant morbidity. The cannabinoid system is an important mediator of the pathophysiology of acute and chronic liver diseases. Experimental data and clinical data indicate that activation of CB1 cannabinoid receptors in peripheral tissues plays a role in insulin resistance and hepatic stéatogenèse, two key steps in the development of metabolic steatopathy. CB1 receptors are also involved in the progression of fibrosis associated with chronic liver disease. All these data suggest that antagonists of cannabinoid CB1 receptor may offer a new therapeutic approach in the NASH.
Source: Cannabinoid receptors as novel therapeutic targets for the management of non-alcoholic steatohepatitis - EM|consulte
Prevalence of non-alcoholic steatohepatitis (NASH) Rises steadily in Western Countries with the obesity epidemic. NASH is associated with activation of liver fibrogenesis and predisposed to cirrhosis and associated morbidity mortalité. The cannabinoid system is increasingly have a crucial mediator emery of acute and chronic liver injury. Recent experimental and clinical data Indicate That activation of peripheral cannabinoid CB1 receptors Promotes insulin resistance and liver steatogenesis, Two key steps in the pathogenesis of non-alcoholic fatty liver disease. Moreover, CB1 receptors Enhance progression of liver fibrogenesis. These Findings provide statement a strong rationale for the use of CB1 antagonists in the management of NASH.
Summary
The prevalence of NASH is increasing in Western countries, along with that of obesity. NASH is associated with activation mechanisms of fibrogenesis with a risk of progression to cirrhosis and significant morbidity. The cannabinoid system is an important mediator of the pathophysiology of acute and chronic liver diseases. Experimental data and clinical data indicate that activation of CB1 cannabinoid receptors in peripheral tissues plays a role in insulin resistance and hepatic stéatogenèse, two key steps in the development of metabolic steatopathy. CB1 receptors are also involved in the progression of fibrosis associated with chronic liver disease. All these data suggest that antagonists of cannabinoid CB1 receptor may offer a new therapeutic approach in the NASH.
Source: Cannabinoid receptors as novel therapeutic targets for the management of non-alcoholic steatohepatitis - EM|consulte
